Company: NCEL
Filing Date: 2025-07-29
Form Type: F-4/A
Source: 0001213900-25-068765
Chunk: 56

Company: NewcelX Ltd.
Filing Date: 2025-07-29
Form: F-4/A
Chunk 56
---
 structure. Article 3c of the articles of association is proposed to be amended as provided in the invitation. 7. Amendment to the Articles regarding the Provisions on the Share Register and Voting Rights The board proposes to change articles 6 and 12 of the articles of association as provided in the invitation. 8. Amendment of the Articles to change the Company Name The board proposes to change the company name to NewcelX AG and that article 1 of the articles of association is amended as provided in the invitation. 9. Election of the new Board of Directors Pursuant to the Merger Agreement, the current members of the Board of Directors (excluding Alexander Zwyer and Olivier Samuel) must resign from their positions immediately prior to the Effective Time (as defined in the Merger Agreement). The board proposes to elect the following persons individually as board members for a term of office until the conclusion of the next ordinary Annual Shareholders Meeting. Detailed information on the proposed board members is provided in the invitation. 9.01 Mr. Ronen Twito as chairman of the Board of Directors: citizen of Israel, residing in Israel 9.02 Prof. Michel Revel as member of the Board of Directors: citizen of Israel, residing in Israel 9.03 Mr. Eran Iohan as member of the Board of Directors: citizen of Israel, residing in Israel 9.04 Ms. Liora Oren as member of the Board of Directors: citizen of Israel, residing in Israel 9.05 Ms. Tammy Galili as member of the Board of Directors: citizen of Israel, residing in Israel FOR AGAINST ABSTAIN NLS PHARMACEUTICS LTD. Extraordinary Meeting of Shareholders August 25, 2025 The undersigned, a shareholder of NLS Pharmaceutics Ltd., (the “Company”), hereby appoints KBT Treuhand AG Zurich as independent proxy; or (full name and address) proxy of the undersigned, with full power of substitution, for and as in the name of the undersigned, to vote and otherwise act on behalf of the undersigned at the extraordinary general meeting of shareholders of the Company to be held on August 25, 2025, at the premises of Baker McKenzie Switzerland AG, Holbeinstrasse 30, 8034 Zurich, Switzerland, at 4 p.m. CET (10 a.m. EST), or at any adjournment(s) or postponement(s) thereof, with respect to all of the common shares of